NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc. (NBSE): 1 pipeline candidate · ~19 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
19.2 months
D/E 1.04 · 0% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for NeuBase Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$12.6M
Quarterly Burn
$2.0M
Runway
19.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| patrol platform | Preclinical |
Frequently asked questions
How many drug candidates are in NeuBase Therapeutics, Inc.'s pipeline?
NeuBase Therapeutics, Inc. (NBSE) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is NeuBase Therapeutics, Inc.'s lead drug candidate?
NeuBase Therapeutics, Inc.'s most advanced tracked candidate is patrol platform (Preclinical) for myotonic dystrophy type 1 ("DM1"), Huntington's disease ("HD"), and oncology.
What is NeuBase Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NeuBase Therapeutics, Inc. has approximately 19.2 months of cash runway.
Who is the CEO of NeuBase Therapeutics, Inc.?
Todd Branning Todd is the chief executive officer of NeuBase Therapeutics, Inc. (NBSE).
Get the full picture on NeuBase Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.